GeneDx Holdings Corp. (WGS) Cash Flow Statement
GeneDx Holdings Corp. (WGS) generated -$48.7M of operating cash flow over the twelve months to 2026-06-30, spent $27.1M on capital expenditure and had free cash flow of -$75.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
WGSGeneDx Holdings Corp.Follow WGS — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 26 Oct, in 2 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -190.4 | -319.2 | -180.1 | -28.5 | 33.3 | -48.7 | |
| Capital expenditure | 20.8 | 7.2 | 5.7 | 5.5 | 19.0 | -27.1 | |
| Free cash flow | -211.2 | -326.3 | -185.9 | -34.0 | 14.3 | -75.8 | |
| Stock-based compensation | 219.4 | 42.0 | -0.3 | 9.1 | 32.2 | — |
USD millions · SEC XBRL
GeneDx Holdings Corp. — questions
- What is GeneDx Holdings Corp.'s operating cash flow?
- -$48.7M over the twelve months to 2026-06-30.
- How much does GeneDx Holdings Corp. spend on capital expenditure?
- $27.1M over the twelve months to 2026-06-30.
- What is GeneDx Holdings Corp.'s free cash flow?
- -$75.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from GeneDx Holdings Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.